logo
Are generic medicines as good as branded ones? Here's what you should know

Are generic medicines as good as branded ones? Here's what you should know

Business Standard15 hours ago
When you pick a generic medicine over a branded one, you're saving money, but how much do you really know about what's in that tablet? PM Modi calls India the 'Pharmacy of the World,' with the pharmaceutical industry valued at around $50 billion in FY24 and expected to grow to $120–130 billion by 2030, according to a December 2024 statement by the Ministry of Chemicals and Fertilisers. Generics drive this growth, contributing 70–80 per cent of India's retail pharma revenue and nearly 100 per cent of volume in some areas.
However, the Central Drugs Standard Control Organisation (CDSCO), under India's Ministry of Health and Family Welfare (MoHFW), which serves as the national regulatory authority for ensuring the safety, efficacy, and quality of pharmaceuticals, has raised some red flags. In April 2025, the CDSCO released yet another list of Not of Standard Quality (NSQ) drugs, highlighting persistent concerns about substandard pharmaceuticals in India.
What are generic medicines and how are they different from branded ones?
A generic medicine is essentially a more affordable version of a branded drug. As Jeevan Kasara, Director and CEO of Steris Healthcare Pvt. Ltd, explained, generics contain the same active ingredient, dosage, strength, and intended use as their branded counterparts.
When a pharmaceutical company's patent expires, other companies are allowed to manufacture the same medicine, usually under its chemical name rather than a branded label.
Do generics differ in dosage, strength, or effectiveness?
Generics are required to match branded medicines in dosage, form, strength, route of administration, and purpose. Minor differences—such as colour, packaging, or inactive ingredients—may exist, but the core active compound remains identical.
Are generic medicines as safe and effective in real life?
Jeevan Kasara stated that reputable manufacturers follow strict regulatory protocols and conduct bioequivalence studies to demonstrate that generics perform the same as branded versions in the body.
CDSCO policies and international audits—such as from the USFDA or European regulators—ensure quality standards, especially for exported generics. Buying from licensed pharmacies and trusted sources is key to safety.
Why do people hesitate to trust generic drugs?
Dr Jagadish Hiremath, a public health expert, said, 'There's a belief that cheaper means lower quality. But that's not true for CDSCO-approved generics.'
Brand familiarity and years of marketing have made some patients wary. In specific cases—like psychiatric, thyroid, or epilepsy medications—doctors may stick with known brands due to sensitivity in absorption rates. But for most common conditions, generics are equally effective.
How much money can you save by choosing generics?
Generic medicines can be 30 to 90 per cent cheaper than branded ones, according to Kasara. For young professionals without insurance, this can translate into major savings over time—without compromising quality.
How can you verify if a generic medicine is trustworthy?
Use this quick safety checklist:
Buy only from licensed pharmacies
Check batch number and expiry date
Look for manufacturing and approval details
Prefer reputed pharmaceutical manufacturers
Apps like Tata 1mg, Netmeds, and Medlife can help verify generic equivalents and manufacturer ratings. Advanced users can consult CDSCO's site or the USFDA Orange Book.
Why don't more doctors prescribe generics openly?
Dr Hiremath attributes it to both caution and habit. Some doctors are concerned about patients using low-quality products from unverified sources. Others are influenced by pharmaceutical marketing and patient preference for known brands.
Are Jan Aushadhi stores helping improve access to generics?
Experts agree that Jan Aushadhi outlets offer an affordable route to essential medicines, especially for those managing chronic illnesses. However, Dr Hiremath emphasised that success depends on robust quality checks, public education, consistent supply chains, and accessible databases.
Should you choose generic or branded medicines?
Here's a quick recap:
For most routine treatments, high-quality generics are just as safe and effective
For specific, sensitive conditions, consult your doctor before switching
Always purchase from trusted pharmacies or platforms
Stay informed and ask questions to make safe, economical decisions
'Saving money should never feel risky when it comes to your health,' said Dr Hiremath. 'Stay informed, ask questions, and choose wisely.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Drug regulator issues list of 17 drugs which should be flushed down if unused or expired
Drug regulator issues list of 17 drugs which should be flushed down if unused or expired

Time of India

time5 hours ago

  • Time of India

Drug regulator issues list of 17 drugs which should be flushed down if unused or expired

NEW DELHI: India's top drug regulatory body, Central Drugs Standard Control Organisation (CDSCO), has released a list of 17 drugs which, it says, should be flushed down the sink if lying unused or expired at home. Tired of too many ads? go ad free now This includes fentanyl, Tramadol and several other painkiller drugs and Diazepam which is an anti-anxiety medication. According to the CDSCO, these drugs may be especially harmful and, in some cases, fatal with just one dose if they are used by someone other than the person for whom the medicine was prescribed. If these drugs are kept unwanted, unused or expired, the drug regulatory body says, they should be flushed down the sink or toilet to prevent danger to people and pets in the home. However, for most other medications used commonly by people, the drug regulatory body in its latest guidelines on disposal of unused/expired drugs recommends that scientific disposal is needed to prevent environmental pollution. For that, it suggests the initiation of 'drug take back' initiative that could be led by either the state drug control department or local chemists initially but eventually, the CDSCO recommends, the state govt in coordination with local bodies needs to establish the methodology and facility for the collection of and disposal of unused or expired drugs as per the provision of Biomedical Waste Management Rules. "Initially, state drugs control departments and concerned chemists and druggists' associations may jointly launch 'drug take back' site programme at designated locations, where people can drop expired or unused drugs from their homes and that can be disposed finally by such associations under intimation to concerned state drug licencing authority with the help of registered/licenced external agencies. The CDSCO guideline follows multiple reports and studies that show how unscientific disposal of unused or unexpired drugs is causing environmental pollution, eventually affecting human life. Tired of too many ads? go ad free now A study by led by Dr T Velpandian of AIIMS' ocular pharmacology division that analysed water samples from seven places in Yamuna river, including the entry and exit points, 35 bore wells in Delhi NCR and the water percolating from waste at Ghazipur landfill site in 2018 showed drugs thrown in the waste bins end up in the environment and contribute to the emergence of multi-drug resistant pathogens. The study showed presence of antibiotics and other drugs in the surface water of river Yamuna and in areas adjacent to the Ghazipur landfill. 'The govt move to formulate a guideline on disposal of unused or expired drugs is commendable. We also plan to develop a pamphlet on how to dispose of drugs that will be given to all patients' said Devarat Majumdar, director and chief of pharmacy at Max healthcare.

Drugs regulator to turn the screws on spurious medical products
Drugs regulator to turn the screws on spurious medical products

Mint

time11 hours ago

  • Mint

Drugs regulator to turn the screws on spurious medical products

New Delhi: India's apex drug regulator—-Central Drugs Standard Control Organisation (CDSCO)—is developing a comprehensive national action plan to combat substandard and spurious medical products, officials and documents said. This follows a World Health Organization (WHO) assessment that highlighted major areas for improvement needed in India's drug regulatory framework. The proposed action plan in the works will implement new prevention, detection and response strategies at both central and state levels. A key focus will be on strengthening the surveillance and control of medical product advertisements aimed at healthcare professionals. The WHO recommended enhanced training and stricter oversight to ensure that all promotional, marketing, and advertising materials provide accurate and non-misleading information about medical products. Further, the CDSCO plans to mandate that all central and state authority websites feature a dedicated reporting page for sub-standard and falsified (spurious) products. Tighter rules for drug ads and easier reporting for public 'As part of the plan, a core component of the CDSCO's revamped approach will be the strengthening of surveillance and control over medical product advertisements, particularly those targeting healthcare professionals. Keeping a closer eye on medical product advertisements will help patients in getting accurate information, safer treatment choices, reduce the dangers of self medication, and better doctor-patient conversations. As per Indian regulations, companies cannot make advertisements of drugs following in schedule H, H1 and X. These drugs are controlled and sold in the prescription of registered medical practitioners," an official said. 'The proposal for implementation of WHO's recommendations were discussed in the Drugs Consultative Committee meeting last month chaired by the Drugs Controller General of India (DCGI). It was agreed upon to take suitable action for each of the recommendations," the official said. Tracking suprious and substandard drugs Notably, one of the important WHO's recommendations is to combat the menace of spurious and sub-standard drugs: preventing, detecting, and responding to "not of standard quality" and "spurious medical drugs," alongside a robust market surveillance program and stringent control over promotional, marketing and advertising activities. The WHO has recommended that all Central and State government websites provide a dedicated 'substandard and falsified (SF) reporting page - with information for the public on how to specifically report SF products. Reports from this mechanism should be subject to the SF report handling procedure for that organization. 'This is an important step towards increased transparency and public participation in identifying or reporting the SF products. This will empower the public to directly report suspicious products and these reports will then be properly investigated," said the official, adding that a communication from DCGI may shortly be released to all the States/UTs to implement the action points in a uniform manner. 'The government is also doing risk-based assessment of pharma firms to keep a track on the drug manufacturing and actions have also been taken," the official said. The Indian pharmaceutical market is set to reach$100 billion by 2025, as per government is the largest provider of generic drugs globally and is also known for its affordable vaccines. 'These measures will not only help protect patients but also safeguard the integrity of compliant pharmaceutical companies," said Nikkhil K. Masurkar, chief executive officer, Entod Pharmaceuticals. Masurkar said that when a spurious or falsified version of a company's drug appears in the market, it triggers significant challenges, even when the original manufacturer has followed all regulatory protocols. 'Patient safety becomes the immediate concern, but the ripple effects are far-reaching. The company can face public scepticism, reputational damage, and erosion of trust among healthcare providers, all because a counterfeit product misrepresents their brand. What makes it more difficult is that the manufacturer is often unfairly perceived as responsible, even when the fault lies entirely with external bad actors. The company is then forced to redirect time, resources, and focus towards legal action, crisis communication, and internal audits, diverting energy from innovation and patient engagement. Despite being the victim, the brand often suffers disproportionately, with long-term reputational impact that's hard to undo." Queries sent to the health ministry spokesperson and WHO remained unanswered.

Godavari Biorefineries secures EU patent for anti-cancer molecule
Godavari Biorefineries secures EU patent for anti-cancer molecule

Fibre2Fashion

time11 hours ago

  • Fibre2Fashion

Godavari Biorefineries secures EU patent for anti-cancer molecule

Godavari Biorefineries Limited (BSE: 544279 | NSE: GODAVARIB) announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. Godavari Biorefineries' anti-cancer molecule patent has been validated in Spain, the UK, and as a Unitary Patent in the EU. Now in Phase 1a trials, the molecule shows promise against various cancers. This milestone boosts GBL's scientific innovation presence, led by Sathgen Therapeutics, and supports its broader push into biotech alongside its core bio-based businesses. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers. "This patent validation marks a significant milestone in our journey toward advancing original, high-quality scientific research," said Sangeeta Srivastava, Executive Director, Godavari Biorefineries Limited. "It reflects the dedication of our teams and our aspiration to contribute meaningfully to global knowledge and innovation." Godavari Biorefineries has established a global presence, exporting to over 20 countries and maintaining strong linkages with international research and development networks. The company's clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is deepening its investment in translational research that addresses some of the world's most urgent health challenges. This development highlights GBL's growing diversification into advanced scientific domains, complementing its leadership in ethanol, bio-based chemicals, and renewable materials produced from agricultural feedstocks. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. ALCHEMPro News Desk (HU)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store